| Overview |
| bs-8304R |
| MTGR1 Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Cow, Pig, Horse, Chicken |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MTGR1 |
| 321-420/604 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 9139 |
| Nucleus |
| AML1 MTG8; CBFA2T2; Core binding factor runt domain alpha subunit 2 translocated to 2; EHT; ETO homolog on chromosome 20; ETO homologous on chromosome 20; MTG 8 like protein; MTG 8 related protein 1; MTG8 like protein; MTG8 related protein 1; MTG8-like protein; MTG8-related protein 1; MTG8R_HUMAN; MTGR 1; Myeloid translocation gene related protein 1; Myeloid translocation related protein 1; Myeloid translocation-related protein 1; p85; Protein CBFA2T2; ZMYND 3; ZMYND3. |
| May function as a complex with the chimeric protein RUNX1/AML1-CBFA2T1/MTG8 which is produced in acute myeloid leukemia with the chromosomal translocation t(8;21). May thus be involved in the repression of AML1-dependent transcription and the induction of G-CSF/CSF3-dependent cell growth. May be a tumor suppressor gene candidate involved in myeloid tumors with the deletion of the 20q11 region.Tissue specificity:Ubiquitously expressed in fetal and adult tissues. Highly expressed in adult brain, heart, lung, kidney, lymph node, appendix, thymus, testis, uterus, small intestine, prostate and thymus. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz